Therapeutic Schedule Evaluation for Brain-Metastasized Non-Small Cell Lung Cancer with A Probabilistic Linguistic ELECTRE II Method

about

Therapeutic Schedule Evaluation for Brain-Metastasized Non-Small Cell Lung Cancer with A Probabilistic Linguistic ELECTRE II Method

Item

http://www.wikidata.org/entity/Q58726051

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Therapeutic Schedule Evaluatio ...... c Linguistic ELECTRE II Method

@en

Therapeutic Schedule Evaluatio ...... c Linguistic ELECTRE II Method

@nl

type

Item

label

Therapeutic Schedule Evaluatio ...... c Linguistic ELECTRE II Method

@en

Therapeutic Schedule Evaluatio ...... c Linguistic ELECTRE II Method

@nl

prefLabel

Therapeutic Schedule Evaluatio ...... c Linguistic ELECTRE II Method

@en

Therapeutic Schedule Evaluatio ...... c Linguistic ELECTRE II Method

@nl

P1476

Therapeutic Schedule Evaluatio ...... c Linguistic ELECTRE II Method

@en

P2093

Ling Pan

http://www.w3.org/2001/XMLSchema#string

Peijia Ren

http://www.w3.org/2001/XMLSchema#string

Zeshui Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer.

Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer: a case report.

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis

Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China

Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea

Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.

P304

1799

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/IJERPH15091799

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-08-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30134591

http://www.w3.org/2001/XMLSchema#string

P932

6163449

http://www.w3.org/2001/XMLSchema#string